Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials

Fotios Barkas; Georgia Anastasiou; Haralampos Milionis; Evangelos Liberopoulos

doi:10.1007/s13340-021-00515-4

Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials

Diabetol Int. 2021 Jun 6;13(1):325-329. doi: 10.1007/s13340-021-00515-4. eCollection 2022 Jan.

Authors

Fotios Barkas¹, Georgia Anastasiou¹, Haralampos Milionis¹, Evangelos Liberopoulos¹

Affiliation

¹ Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45 110, Ioannina, Greece.

Abstract

The present meta-analysis included 8 cardiovascular outcome trials with 57,185 patients at high cardiometabolic risk. In comparison with placebo, treatment with sodium-glucose cotransporter inhibitors was associated with a significantly lower risk of pneumonia (RR 0.85, 95% CI 0.76-0.95, p = 0.004; I ² = 0, p = 0.48).

Supplementary information: The online version contains supplementary material available at 10.1007/s13340-021-00515-4.

Keywords: Canagliflozin; Cardiovascular; Dapagliflozin; Empagliflozin; Ertugliflozin; Sodium-glucose cotransporter inhibitor; Sotagliflozin.